Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 368-373

  Malátková, Petra ^a   Ebert, Bettina ^b   Wsól, Vladimír ^a   Maser, Edmund ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Carbonyl reductase 3; Inflammation; NF B; Transcriptional regulation

Indexed keywords

CARBONYL REDUCTASE; CARBONYL REDUCTASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CELL STRAIN HT29; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALCOHOL OXIDOREDUCTASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HT29 CELLS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84859431471     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.002     Document Type: Article

References (21)

1. Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu. Rev. Pharmacol. Toxicol. 2007, 47:293-322.
2. Matsunaga T., Shintani S., Hara A. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab. Pharmacokinet. 2006, 21:1-18.
3. Watanabe K., Sugawara C., Ono A., Fukuzumi Y., Itakura S., Yamazaki M., Tashiro H., Osoegawa K., Soeda E., Nomura T. Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2. Genomics 1998, 52:95-100.
4. Malatkova P., Maser E., Wsol V. Human carbonyl reductases. Curr. Drug Metab. 2010, 11:639-658.
5. Bains O.S., Karkling M.J., Lubieniecka J.M., Grigliatti T.A., Reid R.E., Riggs K.W. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J. Pharmacol. Exp. Ther. 2010, 332:755-763.
6. Lal S., Sandanaraj E., Wong Z.W., Ang P.C., Wong N.S., Lee E.J., Chowbay B. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008, 99:2045-2054.
7. E.S. Pilka, F.H. Niesen, W.H. Lee, Y. El-Hawari, J.E. Dunford, G. Kochan, V. Wsol, H.J. Martin, E. Maser, U. Oppermann, Structural basis for substrate specificity in human monomeric carbonyl reductases, PLoS One 4 (2009) e7113.
8. Miura T., Nishinaka T., Terada T. Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol. Cell Biochem. 2008, 315:113-121.
9. Ebert B., Kisiela M., Malatkova P., El-Hawari Y., Maser E. Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells. Biochemistry 2010, 49:8499-8511.
10. Cheng Q., Kalabus J.L., Zhang J., Blanco J.G. A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2. Biochem. Pharmacol. 2012, 83:139-148.
11. Zhang J., Blanco J.G. Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression. Pharm. Res. 2009, 26:2209-2215.
12. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011, 21:103-115.
13. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
14. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl):S81-S96.
15. Rahman A., Anwar K.N., True A.L., Malik A.B. Thrombin-induced p65 homodimer binding to downstream NF-kappa B site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion. J. Immunol. 1999, 162:5466-5476.
16. Chen F.E., Ghosh G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene 1999, 18:6845-6852.
17. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684.
18. Ballard D.W., Dixon E.P., Peffer N.J., Bogerd H., Doerre S., Stein B., Greene W.C. The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc. Natl. Acad. Sci. USA 1992, 89:1875-1879.
19. Sonkoly E., Pivarcsi A. MicroRNAs in inflammation. Int. Rev. Immunol. 2009, 28:535-561.
20. Jobin C., Haskill S., Mayer L., Panja A., Sartor R.B. Evidence for altered regulation of I kappa B alpha degradation in human colonic epithelial cells. J. Immunol. 1997, 158:226-234.
21. Han Y., Meng T., Murray N.R., Fields A.P., Brasier A.R. Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory feedback loop in hepatocytes. A role for protein kinase calpha in post-transcriptional regulation of ikappabalpha resynthesis. J. Biol. Chem. 1999, 274:939-947.